GGrantIndex
← Leaderboards

William Austin O'Brien

University Of Texas Medical Br Galveston

$7,154,790
Attributed
$7,154,790
Total exposure
16
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.7M · FY200510
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10

Funding mix

By agency

NIH$7,154,790 · 16

By mechanism

U01$3,636,275 · 1
R01$2,225,331 · 3
R21$480,575 · 2
R43$430,933 · 1
R56$372,910 · 1
M01$6,900 · 6

Top collaborators

No co-investigators on record.

Most similar at University Of Texas Medical Br Galveston

Same institution · by research overlap

Others in their field

Top investigators on “Hiv Infections

Research focus

Hiv InfectionsMacrophageHuman TissueBiological Signal TransductionInstitutionNeurotransmitter TransportTissue /Cell CultureAids Dementia ComplexResearch PersonnelHippocampusPostmortemLaboratory RatNeurotransmitter MetabolismNeural TransmissionFundingArachidonatePlatelet Activating FactorElectrophysiologyProstaglandin EGlutamate ReceptorGlutamatesGrantSynapsesAids Therapy

Grant awards (24)

FINITE ELEMENT SIMULATION OF SOUND WAVE PROPAGATION INTO THE HUMAN HEAD$1,095
P41 · FY2010 · RR · contact PI
Characterization of Cellular Proteins Involved in HIV Infection$430,933
R43 · FY2009 · AI · contact PI
FINITE ELEMENT SIMULATION OF SOUND WAVE PROPAGATION INTO THE HUMAN HEAD$771
P41 · FY2009 · RR · contact PI
ADULT AIDS CLINICAL TRIAL UNIT$456,251
U01 · FY2007 · AI · contact PI
ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS$1,325
M01 · FY2007 · RR · contact PI
ADULT AIDS CLINICAL TRIAL UNIT$623,323
U01 · FY2006 · AI · contact PI
Role of Tetraspan Glycoproteins (CD63) in HIV Entry$372,910
R56 · FY2006 · AI · contact PI
Role of Tetraspan Glycoproteins (CD63) HIV Replication$372,910
R01 · FY2006 · HL · contact PI
ACTG A5223: SEX DIFFERENCES IN LOPINAVIR/RITONAVIR PHARMACOKINETICS AMONG$1,436
M01 · FY2006 · RR · contact PI
ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS$1,436
M01 · FY2006 · RR · contact PI
ACTG A5142: A PHASE III, RANDOMIZED, OPEN-LABEL COMPARISON OF LOPINAVIR/$717
M01 · FY2006 · RR · contact PI
ADULT AIDS CLINICAL TRIAL UNIT$1,314,868
U01 · FY2005 · AI
Role of Tetraspan Glycoproteins (CD63) in HIV Entry$335,250
R01 · FY2005 · AI
ACTG A5210: A PHASE IB/IIA DOSE-FINDING SAFETY AND ACTIVITY STUDY OF AMD 11070$640
M01 · FY2005 · RR
ADULT AIDS CLINICAL TRIAL UNIT$1,241,833
U01 · FY2004 · AI
Role of Tetraspan Glycoproteins (CD63) in HIV Entry$335,250
R01 · FY2004 · AI
ACTG A5143: A RANDOMIZED, COMPARATIVE STUDY OF LOPINAVIR/RITONAVIR VERSUS$1,346
M01 · FY2004 · RR
Role of Tetraspan Glycoproteins (CD63) in HIV Entry$331,943
R01 · FY2003 · AI
LIPID MEDIATORS IN HIV NEUROTRANSMITTER DYSFUNCTION$324,547
R01 · FY2002 · NS
HIV MACROPHAGE TROPISM$294,325
R21 · FY2001 · AI
LIPID MEDIATORS IN HIV NEUROTRANSMITTER DYSFUNCTION$247,512
R01 · FY2001 · NS
BLOCKADE OF CD8+ T CELL DEATH BY CXCR4 INHIBITORS$186,250
R21 · FY2001 · AI
LIPID MEDIATORS IN HIV NEUROTRANSMITTER DYSFUNCTION$34,911
R01 · FY2001 · NS
LIPID MEDIATORS IN HIV NEUROTRANSMITTER DYSFUNCTION$243,008
R01 · FY2000 · NS